Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 133

1.

Eukaryotic initiation factor 4E-binding protein as an oncogene in breast cancer.

Rutkovsky AC, Yeh ES, Guest ST, Findlay VJ, Muise-Helmericks RC, Armeson K, Ethier SP.

BMC Cancer. 2019 May 23;19(1):491. doi: 10.1186/s12885-019-5667-4.

2.

Deletion of the murine ortholog of the 8q24 gene desert has anti-cancer effects in transgenic mammary cancer models.

Homer-Bouthiette C, Zhao Y, Shunkwiler LB, Van Peel B, Garrett-Mayer E, Baird RC, Rissman AI, Guest ST, Ethier SP, John MC, Powers PA, Haag JD, Gould MN, Smits BMG.

BMC Cancer. 2018 Dec 10;18(1):1233. doi: 10.1186/s12885-018-5109-8.

3.

ICOSL-augmented adenoviral-based vaccination induces a bipolar Th17/Th1 T cell response against unglycosylated MUC1 antigen.

Carrell RK, Stanton RA, Ethier SP, LaRue AC, Soloff AC.

Vaccine. 2018 Oct 8;36(42):6262-6269. doi: 10.1016/j.vaccine.2018.09.010. Epub 2018 Sep 12.

PMID:
30219366
4.

Oridonin inhibits aberrant AKT activation in breast cancer.

Sun B, Wang G, Liu H, Liu P, Twal WO, Cheung H, Carroll SL, Ethier SP, Mevers EE, Clardy J, Roberts T, Chen C, Li Q, Wang L, Yang M, Zhao JJ, Wang Q.

Oncotarget. 2018 Feb 1;9(35):23878-23889. doi: 10.18632/oncotarget.24378. eCollection 2018 May 8.

5.

MYC Inhibition Depletes Cancer Stem-like Cells in Triple-Negative Breast Cancer.

Yang A, Qin S, Schulte BA, Ethier SP, Tew KD, Wang GY.

Cancer Res. 2017 Dec 1;77(23):6641-6650. doi: 10.1158/0008-5472.CAN-16-3452. Epub 2017 Sep 26.

6.

Development of mammary hyperplasia, dysplasia, and invasive ductal carcinoma in transgenic mice expressing the 8p11 amplicon oncogene NSD3.

Turner-Ivey B, Smith EL, Rutkovsky AC, Spruill LS, Mills JN, Ethier SP.

Breast Cancer Res Treat. 2017 Jul;164(2):349-358. doi: 10.1007/s10549-017-4258-9. Epub 2017 May 8.

7.

Cancer-associated fibroblast-secreted CXCL16 attracts monocytes to promote stroma activation in triple-negative breast cancers.

Allaoui R, Bergenfelz C, Mohlin S, Hagerling C, Salari K, Werb Z, Anderson RL, Ethier SP, Jirström K, Påhlman S, Bexell D, Tahin B, Johansson ME, Larsson C, Leandersson K.

Nat Commun. 2016 Oct 11;7:13050. doi: 10.1038/ncomms13050.

8.

MYC Is a Crucial Mediator of TGFβ-Induced Invasion in Basal Breast Cancer.

Cichon MA, Moruzzi ME, Shqau TA, Miller E, Mehner C, Ethier SP, Copland JA, Radisky ES, Radisky DC.

Cancer Res. 2016 Jun 15;76(12):3520-30. doi: 10.1158/0008-5472.CAN-15-3465. Epub 2016 Apr 13.

9.

Functional oncogene signatures guide rationally designed combination therapies to synergistically induce breast cancer cell death.

Guest ST, Kratche ZR, Irish JC, Wilson RC, Haddad R, Gray JW, Garrett-Mayer E, Ethier SP.

Oncotarget. 2016 Jun 14;7(24):36138-36153. doi: 10.18632/oncotarget.9147.

10.

Amplification of WHSC1L1 regulates expression and estrogen-independent activation of ERα in SUM-44 breast cancer cells and is associated with ERα over-expression in breast cancer.

Irish JC, Mills JN, Turner-Ivey B, Wilson RC, Guest ST, Rutkovsky A, Dombkowski A, Kappler CS, Hardiman G, Ethier SP.

Mol Oncol. 2016 Jun;10(6):850-65. doi: 10.1016/j.molonc.2016.02.003. Epub 2016 Feb 27.

11.

Overexpression of GAB2 in ovarian cancer cells promotes tumor growth and angiogenesis by upregulating chemokine expression.

Duckworth C, Zhang L, Carroll SL, Ethier SP, Cheung HW.

Oncogene. 2016 Aug 4;35(31):4036-47. doi: 10.1038/onc.2015.472. Epub 2015 Dec 14.

12.

The culture of cell culture practices and authentication--Results from a 2015 Survey.

Freedman LP, Gibson MC, Wisman R, Ethier SP, Soule HR, Reid YA, Neve RM.

Biotechniques. 2015 Oct 1;59(4):189-90, 192. doi: 10.2144/000114344. eCollection 2015 Oct. No abstract available.

13.

Expression of functional toll like receptor 4 in estrogen receptor/progesterone receptor-negative breast cancer.

Mehmeti M, Allaoui R, Bergenfelz C, Saal LH, Ethier SP, Johansson ME, Jirström K, Leandersson K.

Breast Cancer Res. 2015 Sep 22;17:130. doi: 10.1186/s13058-015-0640-x.

14.

Perspectives on Epidermal Growth Factor Receptor Regulation in Triple-Negative Breast Cancer: Ligand-Mediated Mechanisms of Receptor Regulation and Potential for Clinical Targeting.

Williams CB, Soloff AC, Ethier SP, Yeh ES.

Adv Cancer Res. 2015;127:253-81. doi: 10.1016/bs.acr.2015.04.008. Epub 2015 May 8. Review.

PMID:
26093903
15.

Reproducibility: changing the policies and culture of cell line authentication.

Freedman LP, Gibson MC, Ethier SP, Soule HR, Neve RM, Reid YA.

Nat Methods. 2015 Jun;12(6):493-7. doi: 10.1038/nmeth.3403. No abstract available.

PMID:
26020501
16.

Two members of the TRiC chaperonin complex, CCT2 and TCP1 are essential for survival of breast cancer cells and are linked to driving oncogenes.

Guest ST, Kratche ZR, Bollig-Fischer A, Haddad R, Ethier SP.

Exp Cell Res. 2015 Mar 15;332(2):223-35. doi: 10.1016/j.yexcr.2015.02.005. Epub 2015 Feb 20.

PMID:
25704758
17.

Oncogenic signaling in amphiregulin and EGFR-expressing PTEN-null human breast cancer.

Kappler CS, Guest ST, Irish JC, Garrett-Mayer E, Kratche Z, Wilson RC, Ethier SP.

Mol Oncol. 2015 Feb;9(2):527-43. doi: 10.1016/j.molonc.2014.10.006. Epub 2014 Oct 23.

18.

SNAI2 modulates colorectal cancer 5-fluorouracil sensitivity through miR145 repression.

Findlay VJ, Wang C, Nogueira LM, Hurst K, Quirk D, Ethier SP, Staveley O'Carroll KF, Watson DK, Camp ER.

Mol Cancer Ther. 2014 Nov;13(11):2713-26. doi: 10.1158/1535-7163.MCT-14-0207. Epub 2014 Sep 23.

19.

KAT6A, a chromatin modifier from the 8p11-p12 amplicon is a candidate oncogene in luminal breast cancer.

Turner-Ivey B, Guest ST, Irish JC, Kappler CS, Garrett-Mayer E, Wilson RC, Ethier SP.

Neoplasia. 2014 Aug;16(8):644-55. doi: 10.1016/j.neo.2014.07.007.

20.

Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target.

Timmerman LA, Holton T, Yuneva M, Louie RJ, Padró M, Daemen A, Hu M, Chan DA, Ethier SP, van 't Veer LJ, Polyak K, McCormick F, Gray JW.

Cancer Cell. 2013 Oct 14;24(4):450-65. doi: 10.1016/j.ccr.2013.08.020. Epub 2013 Oct 3.

21.

Global H3K27 trimethylation and EZH2 abundance in breast tumor subtypes.

Holm K, Grabau D, Lövgren K, Aradottir S, Gruvberger-Saal S, Howlin J, Saal LH, Ethier SP, Bendahl PO, Stål O, Malmström P, Fernö M, Rydén L, Hegardt C, Borg Å, Ringnér M.

Mol Oncol. 2012 Oct;6(5):494-506. doi: 10.1016/j.molonc.2012.06.002. Epub 2012 Jun 20.

22.

Induction of proapoptotic antibodies to triple-negative breast cancer by vaccination with TRAIL death receptor DR5 DNA.

Piechocki MP, Wu GS, Jones RF, Jacob JB, Gibson H, Ethier SP, Abrams J, Yagita H, Venuprasad K, Wei WZ.

Int J Cancer. 2012 Dec 1;131(11):2562-72. doi: 10.1002/ijc.27534. Epub 2012 Apr 24.

23.

Identification and functional analysis of 9p24 amplified genes in human breast cancer.

Wu J, Liu S, Liu G, Dombkowski A, Abrams J, Martin-Trevino R, Wicha MS, Ethier SP, Yang ZQ.

Oncogene. 2012 Jan 19;31(3):333-41. doi: 10.1038/onc.2011.227. Epub 2011 Jun 13.

24.

Oncogene activation induces metabolic transformation resulting in insulin-independence in human breast cancer cells.

Bollig-Fischer A, Dewey TG, Ethier SP.

PLoS One. 2011 Mar 17;6(3):e17959. doi: 10.1371/journal.pone.0017959.

25.

Frequency and type of epidermal growth factor receptor mutations in African Americans with non-small cell lung cancer.

Cote ML, Haddad R, Edwards DJ, Atikukke G, Gadgeel S, Soubani AO, Lonardo F, Bepler G, Schwartz AG, Ethier SP.

J Thorac Oncol. 2011 Mar;6(3):627-30. doi: 10.1097/JTO.0b013e31820a0ec0.

26.

Knock-down of amphiregulin inhibits cellular invasion in inflammatory breast cancer.

Baillo A, Giroux C, Ethier SP.

J Cell Physiol. 2011 Oct;226(10):2691-701. doi: 10.1002/jcp.22620.

27.

Forkhead transcription factor foxq1 promotes epithelial-mesenchymal transition and breast cancer metastasis.

Zhang H, Meng F, Liu G, Zhang B, Zhu J, Wu F, Ethier SP, Miller F, Wu G.

Cancer Res. 2011 Feb 15;71(4):1292-301. doi: 10.1158/0008-5472.CAN-10-2825. Epub 2011 Feb 1.

28.

Transforming properties of 8p11-12 amplified genes in human breast cancer.

Yang ZQ, Liu G, Bollig-Fischer A, Giroux CN, Ethier SP.

Cancer Res. 2010 Nov 1;70(21):8487-97. doi: 10.1158/0008-5472.CAN-10-1013. Epub 2010 Oct 12.

29.

HER-2 signaling, acquisition of growth factor independence, and regulation of biological networks associated with cell transformation.

Bollig-Fischer A, Dziubinski M, Boyer A, Haddad R, Giroux CN, Ethier SP.

Cancer Res. 2010 Oct 15;70(20):7862-73. doi: 10.1158/0008-5472.CAN-10-1529. Epub 2010 Aug 24.

30.

EGFR/Met association regulates EGFR TKI resistance in breast cancer.

Mueller KL, Yang ZQ, Haddad R, Ethier SP, Boerner JL.

J Mol Signal. 2010 Jul 12;5:8. doi: 10.1186/1750-2187-5-8.

31.

Disulfiram treatment facilitates phosphoinositide 3-kinase inhibition in human breast cancer cells in vitro and in vivo.

Zhang H, Chen D, Ringler J, Chen W, Cui QC, Ethier SP, Dou QP, Wu G.

Cancer Res. 2010 May 15;70(10):3996-4004. doi: 10.1158/0008-5472.CAN-09-3752. Epub 2010 Apr 27.

32.

Genomic amplification and oncogenic properties of the GASC1 histone demethylase gene in breast cancer.

Liu G, Bollig-Fischer A, Kreike B, van de Vijver MJ, Abrams J, Ethier SP, Yang ZQ.

Oncogene. 2009 Dec 17;28(50):4491-500. doi: 10.1038/onc.2009.297. Epub 2009 Sep 28.

33.

Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines.

Hollestelle A, Nagel JH, Smid M, Lam S, Elstrodt F, Wasielewski M, Ng SS, French PJ, Peeters JK, Rozendaal MJ, Riaz M, Koopman DG, Ten Hagen TL, de Leeuw BH, Zwarthoff EC, Teunisse A, van der Spek PJ, Klijn JG, Dinjens WN, Ethier SP, Clevers H, Jochemsen AG, den Bakker MA, Foekens JA, Martens JW, Schutte M.

Breast Cancer Res Treat. 2010 May;121(1):53-64. doi: 10.1007/s10549-009-0460-8. Epub 2009 Jul 11.

PMID:
19593635
34.

Methylation-associated silencing of SFRP1 with an 8p11-12 amplification inhibits canonical and non-canonical WNT pathways in breast cancers.

Yang ZQ, Liu G, Bollig-Fischer A, Haddad R, Tarca AL, Ethier SP.

Int J Cancer. 2009 Oct 1;125(7):1613-21. doi: 10.1002/ijc.24518.

35.

Activation of Src by protein tyrosine phosphatase 1B Is required for ErbB2 transformation of human breast epithelial cells.

Arias-Romero LE, Saha S, Villamar-Cruz O, Yip SC, Ethier SP, Zhang ZY, Chernoff J.

Cancer Res. 2009 Jun 1;69(11):4582-8. doi: 10.1158/0008-5472.CAN-08-4001. Epub 2009 May 12.

36.

Racial disparity in breast cancer and functional germ line mutation in galectin-3 (rs4644): a pilot study.

Balan V, Nangia-Makker P, Schwartz AG, Jung YS, Tait L, Hogan V, Raz T, Wang Y, Yang ZQ, Wu GS, Guo Y, Li H, Abrams J, Couch FJ, Lingle WL, Lloyd RV, Ethier SP, Tainsky MA, Raz A.

Cancer Res. 2008 Dec 15;68(24):10045-50. doi: 10.1158/0008-5472.CAN-08-3224.

37.

ERRgamma mediates tamoxifen resistance in novel models of invasive lobular breast cancer.

Riggins RB, Lan JP, Zhu Y, Klimach U, Zwart A, Cavalli LR, Haddad BR, Chen L, Gong T, Xuan J, Ethier SP, Clarke R.

Cancer Res. 2008 Nov 1;68(21):8908-17. doi: 10.1158/0008-5472.CAN-08-2669. Erratum in: Cancer Res. 2009 Feb 15;69(4):1695. Zhu, Yuelin [added].

38.

Altered EGFR localization and degradation in human breast cancer cells with an amphiregulin/EGFR autocrine loop.

Willmarth NE, Baillo A, Dziubinski ML, Wilson K, Riese DJ 2nd, Ethier SP.

Cell Signal. 2009 Feb;21(2):212-9. doi: 10.1016/j.cellsig.2008.10.003. Epub 2008 Oct 14.

39.

Met and c-Src cooperate to compensate for loss of epidermal growth factor receptor kinase activity in breast cancer cells.

Mueller KL, Hunter LA, Ethier SP, Boerner JL.

Cancer Res. 2008 May 1;68(9):3314-22. doi: 10.1158/0008-5472.CAN-08-0132.

40.

Amphiregulin as a novel target for breast cancer therapy.

Willmarth NE, Ethier SP.

J Mammary Gland Biol Neoplasia. 2008 Jun;13(2):171-9. doi: 10.1007/s10911-008-9081-9. Epub 2008 Apr 25. Review.

PMID:
18437539
41.

Deleterious CHEK2 1100delC and L303X mutants identified among 38 human breast cancer cell lines.

Wasielewski M, Hanifi-Moghaddam P, Hollestelle A, Merajver SD, van den Ouweland A, Klijn JG, Ethier SP, Schutte M.

Breast Cancer Res Treat. 2009 Jan;113(2):285-91. doi: 10.1007/s10549-008-9942-3. Epub 2008 Feb 24.

PMID:
18297428
42.

Comprehensive analysis of oncogenic effects of PIK3CA mutations in human mammary epithelial cells.

Zhang H, Liu G, Dziubinski M, Yang Z, Ethier SP, Wu G.

Breast Cancer Res Treat. 2008 Nov;112(2):217-27. Epub 2007 Dec 12.

PMID:
18074223
43.

Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair.

Saal LH, Gruvberger-Saal SK, Persson C, Lövgren K, Jumppanen M, Staaf J, Jönsson G, Pires MM, Maurer M, Holm K, Koujak S, Subramaniyam S, Vallon-Christersson J, Olsson H, Su T, Memeo L, Ludwig T, Ethier SP, Krogh M, Szabolcs M, Murty VV, Isola J, Hibshoosh H, Parsons R, Borg A.

Nat Genet. 2008 Jan;40(1):102-7. Epub 2007 Dec 9.

44.

Activation of a nuclear factor kappaB/interleukin-1 positive feedback loop by amphiregulin in human breast cancer cells.

Streicher KL, Willmarth NE, Garcia J, Boerner JL, Dewey TG, Ethier SP.

Mol Cancer Res. 2007 Aug;5(8):847-61. Epub 2007 Aug 1.

45.

p38MAPK-activated AKT in HER-2 overexpressing human breast cancer cells acts as an EGF-independent survival signal.

Diehl KM, Grewal N, Ethier SP, Woods-Ignatoski KM.

J Surg Res. 2007 Sep;142(1):162-9. Epub 2007 Jul 5.

PMID:
17612563
46.

Transforming properties of TC-1 in human breast cancer: interaction with FGFR2 and beta-catenin signaling pathways.

Yang ZQ, Moffa AB, Haddad R, Streicher KL, Ethier SP.

Int J Cancer. 2007 Sep 15;121(6):1265-73.

47.

LOXL1 and LOXL4 are epigenetically silenced and can inhibit ras/extracellular signal-regulated kinase signaling pathway in human bladder cancer.

Wu G, Guo Z, Chang X, Kim MS, Nagpal JK, Liu J, Maki JM, Kivirikko KI, Ethier SP, Trink B, Sidransky D.

Cancer Res. 2007 May 1;67(9):4123-9. Epub 2007 Apr 24.

48.

Multiple interacting oncogenes on the 8p11-p12 amplicon in human breast cancer.

Yang ZQ, Streicher KL, Ray ME, Abrams J, Ethier SP.

Cancer Res. 2006 Dec 15;66(24):11632-43.

49.

Supplemental Content

Loading ...
Support Center